Abstract: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the In preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: The (R) and (S) enantiomers of a compound of formula I are novel antiproliferative therapeutic agents. These compounds have HDAC inhibitor activity and are useful in the treatment of cancer. Also disclosed are methods of making and using compounds of formula (I), as well as pharmaceutical compositions containing compounds of formula (I).

Abstract: The (R) and (S) enantiomers of a compound of formula I 1

Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, X and Y have the meanings defined in the specification. The compounds have histone deacetylase (HDAC) inhibitory activity which is useful in cancer treatment. Also provided is a process for making a compound of formula I by reacting a compound of formula III with a compound of formula IV wherein A is a displaceable group and PG is a protecting group.

Abstract: Compounds of formula I wherein R1, R2, A, X, Y and Z have the meanings provided in the specification, and their enantiomers, diastereoisomers, racemates, pharmaceutically acceptable salts and mixtures thereof. These compounds have HDAC inhibitory activity for inhibiting cell proliferation. Also provided is a process of manufacturing these compounds.

Abstract: Compounds of formula I 1

Abstract: The present invention provides compounds of formula I 1

Abstract: Use of compounds of the formula I ##STR1## in which R.sub.1 signifies an amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino or a hydroxyl group, R.sub.2 and R.sub.3, which are the same or different, each hydrogen, halogen, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, cyano, carboxyl, halogen-C.sub.1 -C.sub.6 -alkyl, cyano-C.sub.1 -C.sub.6 -alkyl, carboxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 - alkyl, hydroxyl, carboxy-C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxycarbonyl-C.sub.1 -C.sub.6 -alkoxy or aminocarbonyl-C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylaminocarbonyl-C.sub.1 -C.sub.6 -alkoxy or di-C.sub.1 -C.sub.6 -alkylaminocarbonyl-C.sub.1 -C.sub.6 -alkoxy and n the number 0 or 1, their tautomers, as well as salts with non-toxic acids or bases, for the preparation of medicaments with PLA.sub.2 -inhibiting action, new compounds and process for their preparation.

Abstract: The invention provides for monoclonal antibodies which specifically bind to type I phospholipase A.sub.2 for use as a diagnostic agent and as an anti-inflammatory therapeutic agent, which is particularly suitable for application in acute pancreatitis. The invention further provides for pharmaceutical compositions including the antibodies of the invention. The invention also provides for a method for treating subjects suffering from inflammatory symptoms and for detecting the activity of type I phospholipase A.sub.2 in a sample.

Abstract: Use of compounds of formula I ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, Y and Z have the meanings stated in the claims, tautomers thereof as well as their salts with non-toxic acids or bases for the production of pharmaceutical agents having an inhibitory action on PLA.sub.2 in addition to compounds of formula I in which X does not denote a valency and processes for the production thereof.

Abstract: Compounds of formula I ##STR1## in which Q denotes hydrogen, a hydroxy group or a C.sub.1 to C.sub.8 alkoxy group which can be substituted if desired, by carboxyl or C.sub.1 to C.sub.6 alkoxycarbonyl and eitherY and Z together form a group ##STR2## and X represents hydrogen, C.sub.1 to C.sub.6 alkyl or C.sub.2 to C.sub.6 alkenyl orY and X together form a group ##STR3## or an alkylene residue of 2-4 carbon atoms and Z represents hydrogen, C.sub.1 to C.sub.6 alkyl or C.sub.1 to C.sub.6 alkanoyl, whereR denotes hydrogen or a C.sub.1 to C.sub.6 alkyl residue as well as physiologically tolerated salts thereof, processes for their production and pharmaceutical agents containing these compounds for the treatment of inflammatory diseases and allergic diseases.

Abstract: Medicines are prepared having a synergistic effect containing a combination of the analgesic Flupirtin and at least one non-steroidal antiphlogistic.

Abstract: A synergistic effect is noted when Flupirtin is combined with an anticholinergic spasmolytic.